- Home
- BLNK vs SNTI Comparison
BLNK vs SNTI Comparison
Compare BLNK & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- SNTI
- Stock Information
- Founded
- BLNK 2009
- SNTI 2016
- Country
- BLNK United States
- SNTI United States
- Employees
- BLNK N/A
- SNTI N/A
- Industry
- BLNK Industrial Specialties
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- SNTI Health Care
- Exchange
- BLNK Nasdaq
- SNTI Nasdaq
- Market Cap
- BLNK 77.3M
- SNTI 85.3M
- IPO Year
- BLNK N/A
- SNTI N/A
- Fundamental
- Price
- BLNK $0.92
- SNTI $2.11
- Analyst Decision
- BLNK Buy
- SNTI Strong Buy
- Analyst Count
- BLNK 8
- SNTI 2
- Target Price
- BLNK $2.61
- SNTI $8.50
- AVG Volume (30 Days)
- BLNK 4.3M
- SNTI 369.7K
- Earning Date
- BLNK 08-06-2025
- SNTI 08-12-2025
- Dividend Yield
- BLNK N/A
- SNTI N/A
- EPS Growth
- BLNK N/A
- SNTI N/A
- EPS
- BLNK N/A
- SNTI N/A
- Revenue
- BLNK $109,383,000.00
- SNTI N/A
- Revenue This Year
- BLNK N/A
- SNTI N/A
- Revenue Next Year
- BLNK $31.15
- SNTI $150.00
- P/E Ratio
- BLNK N/A
- SNTI N/A
- Revenue Growth
- BLNK N/A
- SNTI N/A
- 52 Week Low
- BLNK $0.63
- SNTI $1.52
- 52 Week High
- BLNK $3.75
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- BLNK 62.97
- SNTI 34.04
- Support Level
- BLNK $0.85
- SNTI $1.90
- Resistance Level
- BLNK $0.98
- SNTI $3.40
- Average True Range (ATR)
- BLNK 0.09
- SNTI 0.42
- MACD
- BLNK 0.01
- SNTI -0.09
- Stochastic Oscillator
- BLNK 71.43
- SNTI 10.58
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.